Literature DB >> 16313258

Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients.

Xingbing Wang1, Jine Zheng, Jun Liu, Junxia Yao, Yanli He, Xiaoqing Li, Jingming Yu, Jing Yang, Zhongping Liu, Shiang Huang.   

Abstract

PURPOSE: Regulatory T cells (T-reg) that control harmful autoimmune T cells in the periphery may also suppress the immune response against cancer. In this study we investigated the possible involvement of CD4(+)CD25(high) T-reg in the immune impairment of patients with acute myeloid leukemia (AML). EXPERIMENTAL
DESIGN: The frequencies and phenotypes of CD4(+)CD25(high) T cells in the peripheral blood of AML patients were determined by flow cytometry. To assess the functional activity of CD4(+)CD25(high) T cells, CD4(+)CD25(high), and CD4(+)CD25(-) T cells were sorted from peripheral blood mononuclear cells with FACS Vantage. The immunoregulatory properties of CD4(+)CD25(high) and CD4(+)CD25(-) T cells were characterized by proliferation assays and cytokine production assays. In addition, the frequency of apoptotic and proliferating cells in CD4(+)CD25(high) T cells were respectively evaluated by 7AAD and ki67 binding cells using flow cytometry.
RESULTS: Compared with healthy controls, AML patients had a higher proportion of CD4(+)CD25(high) T cells in peripheral blood. These cells were CD45-RA(-), CD69(-), CD45-RO(+), CD95(+), and intercellular CTLA-4(+), and secreted low levels of TNF-alpha and IL-10, but no IL-2, IL-4, IL-5, and IFN-gamma. They inhibited the proliferation and cytokine production (IL-2, IFN-gamma) of CD4(+)CD25(-) T cells, but improved IL-10 production under the co-culture of both subsets with stimulation, thus behaving as T-reg. Notably, CD4(+)CD25(high) T cells in AML patients presented significantly higher apoptosis and proliferation than that of healthy individuals.
CONCLUSIONS: The frequency of CD4(+)CD25(high) T-reg in peripheral blood in AML patients is significantly higher when compared with healthy individuals, likely due to the increasing proliferation of CD4(+)CD25(high) T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16313258     DOI: 10.1111/j.1600-0609.2005.00537.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  48 in total

Review 1.  Evaluation of current cancer immunotherapy: hemato-oncology.

Authors:  Christopher S Hourigan; Hyam I Levitsky
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

2.  Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.

Authors:  Merav Bar; Megan Othus; Hanahlyn M Park; Vicky Sandhu; Xueyan Chen; Brent L Wood; Elihu Estey
Journal:  Leuk Lymphoma       Date:  2015-05-12

3.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

Review 4.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors:  Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

Review 5.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

Review 6.  Programmed death-1 checkpoint blockade in acute myeloid leukemia.

Authors:  Alison Sehgal; Theresa L Whiteside; Michael Boyiadzis
Journal:  Expert Opin Biol Ther       Date:  2015-06-03       Impact factor: 4.388

7.  TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.

Authors:  David A Sallman; Amy F McLemore; Amy L Aldrich; Rami S Komrokji; Kathy L McGraw; Abhishek Dhawan; Susan Geyer; Hsin-An Hou; Erika A Eksioglu; Amy Sullivan; Sarah Warren; Kyle J MacBeth; Manja Meggendorfer; Torsten Haferlach; Steffen Boettcher; Benjamin L Ebert; Najla H Al Ali; Jeffrey E Lancet; John L Cleveland; Eric Padron; Alan F List
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

Review 8.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

9.  Inherited variation in immune genes and pathways and glioblastoma risk.

Authors:  Judith A Schwartzbaum; Yuanyuan Xiao; Yanhong Liu; Spyros Tsavachidis; Mitchel S Berger; Melissa L Bondy; Jeffrey S Chang; Susan M Chang; Paul A Decker; Bo Ding; Sarah J Hepworth; Richard S Houlston; Fay J Hosking; Robert B Jenkins; Matthew L Kosel; Lucie S McCoy; Patricia A McKinney; Kenneth Muir; Joe S Patoka; Michael Prados; Terri Rice; Lindsay B Robertson; Minouk J Schoemaker; Sanjay Shete; Anthony J Swerdlow; Joe L Wiemels; John K Wiencke; Ping Yang; Margaret R Wrensch
Journal:  Carcinogenesis       Date:  2010-07-28       Impact factor: 4.944

10.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.